TARA · CIK 0001359931 · operating
Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. The company's lead program, TARA-002, is an investigational cell therapy currently in Phase II clinical trials for non-muscle invasive bladder cancer and lymphatic malformations. Additionally, Protara is developing intravenous choline chloride, a phospholipid substrate replacement therapy intended for patients receiving parenteral nutrition and intravenous fluids.
The company operates as a pre-revenue clinical-stage entity with a research and development focus. With 28 full-time employees based in New York, Protara maintains a lean operational structure typical of early-stage therapeutic development firms. The company is listed on Nasdaq with a market capitalization of approximately $0.3 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.17 | $-2.17 | +39.2% | |
| 2023 | $-3.57 | $-3.57 | +39.1% | |
| 2022 | $-5.86 | $-5.86 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-05 | 0001213900-25-020368 | SEC ↗ |
| 2023-12-31 | 2024-03-13 | 0001213900-24-021982 | SEC ↗ |
| 2022-12-31 | 2023-03-08 | 0001213900-23-018373 | SEC ↗ |
| 2021-12-31 | 2022-03-09 | 0001213900-22-011208 | SEC ↗ |
| 2020-12-31 | 2021-03-11 | 0001213900-21-014709 | SEC ↗ |
| 2019-12-31 | 2020-03-20 | 0001171843-20-001860 | SEC ↗ |
| 2018-12-31 | 2019-03-13 | 0001171843-19-001687 | SEC ↗ |
| 2017-12-31 | 2018-03-14 | 0001171843-18-001934 | SEC ↗ |
| 2016-12-31 | 2017-03-16 | 0001171843-17-001555 | SEC ↗ |
| 2015-12-31 | 2016-03-14 | 0001171843-16-008541 | SEC ↗ |
| 2014-12-31 | 2015-03-20 | 0001171843-15-001528 | SEC ↗ |